In accordance with prior literature, we hypothesize that CSF biomarkers, particularly p-tau and t-tau, will demonstrate stronger correlations with cognitive decline measures than Aβ1–42, and that these associations will vary across different cognitive domains and stages of impairment. This evidence concerns the gene MAPT and Mental deterioration.